Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2003

View Archived Issues

Improved results described for topical AA-2500 testosterone gel in male hypogonadism

Diversa acquires GlaxoSmithKline antifungal program

Potential efficacy of topiramate in long-term treatment of obesity

Pyridoquinoxaline DNA polymerase inhibitors for herpesvirus infections

New mGluR5 antagonists, their preparation and use reported by Merck

Novel VR1 antagonists and their use in pain and urinary incontinence

Recent patent covers novel factor Xa inhibitors

CV Technologies describes new agents with utility in depression and neuroprotection

New PPARalpha and/or PPARgamma agonists in Biovitrum pipeline

Erectile function and treatment satisfaction best following penile implant surgery

Inhibition of inducible nitric oxide synthase has therapeutic potential in asthma

Simultaneous use of repaglinide and gemfibrozil may increase risk of hypoglycemia

Tanabe Seiyaku to market valganciclovir in Japan

Ciprodex Otic approved for two ear infection indications

Skyepharma submits DepoMorphine NDA

Two new INDs cleared for Thymoglobulin

Roche acquires Cardion's IL-15 antagonist

Preclinical evaluation of A-350619: a potential novel treatment for sexual dysfunction

NO-releasing NCX-972 is more potent than metronidazole in killing E. histolytica

Selective MRP1-mediated multidrug resistant modulator characterized by Vertex

NO-releasing ciprofloxacin active against M. tuberculosis in vitro

BMS evaluates the potential of agonist antibodies targeting CD137 for antitumor therapy

WX-508, an orally available uPA inhibitor as a promising new cancer therapeutic

G-quartet oligodeoxynucleotide targeting Stat3 demonstrates antitumor activity

UMass team discovers small-molecule inhibitors of Tat-TAR with anti-HIV activity

Discodermolide analogue NC2-86 has promising biological profile

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...